Eli Lilly adds Harvard professor as 14th director
INDIANAPOLIS—Drugmaker Eli Lilly and Co. said Monday its board of directors elected Harvard Professor Katherine Baicker as its 14th member.
Baicker, 40, will serve on the board's public policy and compliance committees. Lilly said will serve under an interim status and then stand for election at the company's annual meeting next April.
A company spokesman said Baicker is an addition to the board and is not replacing another board member.
Baicker is a professor of health economics in the Department of Health and Policy Management at the Harvard School of Public Health. Her research includes the fields of health, public and labor economics and focuses mostly on factors that drive the distribution, generosity and effectiveness of public and private health insurance.
The Indianapolis drugmaker's products include the antipsychotic Zyprexa, which recently lost U.S. patent protection, and the antidepressant Cymbalta.
Shares of Lilly fell 51 cents to $38.76 in afternoon trading, while broader trading indexes dropped about 2 percent.